| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-058129 |
| cik | 1607678 |
| name | VIKING THERAPEUTICS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | SAN DIEGO |
| zipba | 92121 |
| bas1 | 9920 PACIFIC HEIGHTS BLVD, SUITE 350 |
| bas2 | |
| baph | 858-704-4660 |
| countryma | US |
| stprma | CA |
| cityma | SAN DIEGO |
| zipma | 92121 |
| mas1 | 9920 PACIFIC HEIGHTS BLVD, SUITE 350 |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 461073877 |
| former | |
| changed | |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250424 |
| accepted | 2025-04-24 16:38:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | vktx-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-058129 | 20240331 | Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition | 7981000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20250331 | Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -216000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Assets | 866993000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Available For Sale Securities Debt Securities Current | 0.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= Cash Equivalents; | ||
| 0000950170-25-058129 | 20250331 | Cash And Cash Equivalents At Carrying Value | 37940000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-058129 | 20240331 | Comprehensive Income Net Of Tax | -28566000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -48000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Increase Decrease In Operating Lease Liability | -88000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Interest Income Expense Nonoperating Net | 9864000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Operating Lease Liability Current | 489000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | 9000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 563000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Prepaid Clinical Trial And Preclinical Study Costs | 13300000.0000 | USD | 0 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20240331 | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 4361000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 7367000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= General And Administrative Expense; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 3981000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Research And Development Expense; | ||
| 0000950170-25-058129 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -377944000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-058129 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -1599000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -216000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20250331 | Stock Issued During Period Values Equity Incentive Awards | 349000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20250331 | Stock Issued During Period Values Equity Incentive Awards | 349000.0000 | USD | 1 | 0000950170-25-058129 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20240331 | Amortization Of Financing Costs Equity Transactions | 28000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20241231 | Assets | 908321000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Cash And Cash Equivalents At Carrying Value | 26676000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Change In Accrued Interest Relating To Marketable Securities Held As Investments | -655000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20250331 | Common Stock Shares Authorized | 300000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | General And Administrative Expense | 14078000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Increase Decrease In Accounts Payable | -2110000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -1748000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Liabilities Current | 27413000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Liabilities Noncurrent | 502000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Net Cash Provided By Used In Financing Activities | 349000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Net Cash Provided By Used In Investing Activities | 63245000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Net Income Loss | -27356000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-058129 | 20250331 | Net Income Loss | -45629000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Operating Expenses | 34073000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Operating Lease Liability Noncurrent | 630000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Operating Lease Right Of Use Asset Amortization Expense | 111000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Other Accrued Liabilities Current | 17111000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | -85000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 349000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Proceeds From Sale Maturity And Collections Of Investments | 295859000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Share Based Compensation | 2153000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= Research And Development Expense; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 8700000.0000 | USD | 9 | us-gaap/2024 | Award Date= January Two Thousand Twenty Three; Award Type= Performance Based Restricted Stock Units; | ||
| 0000950170-25-058129 | 20240331 | Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition | 7981000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Available For Sale Securities Debt Securities Current | 813918000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-058129 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240531 | Common Stock Shares Authorized | 12000000.0000 | shares | 0 | us-gaap/2024 | Plan Name= Two Thousand Twenty Four Equity Incentive Plan; | ||
| 0000950170-25-058129 | 20250331 | Deferred Financing Costs Non Current | 32000.0000 | USD | 0 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20250331 | Earnings Per Share Diluted | -0.4100 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Increase Decrease In Accrued Liabilities | 15923000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Increase Decrease In Accrued Liabilities | -5739000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Liabilities Noncurrent | 630000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Operating Income Loss | -34073000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Operating Income Loss | -55469000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Operating Lease Right Of Use Asset | 892000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Operating Leases Interest Expense | 9000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20240331 | Payments To Acquire Investments | 596601000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Preferred Stock Value | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-058129 | 20250331 | Prepaid Expense And Other Assets Current | 865000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Research And Development Expense | 24103000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Retained Earnings Accumulated Deficit | -533536000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Share Based Compensation | 7981000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Share Based Compensation | 5056000.0000 | USD | 1 | us-gaap/2024 | Award Type= Restricted Stock And Restricted Stock Units; | ||
| 0000950170-25-058129 | 20231231 | Shares Issued | 100113770.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20241231 | Shares Issued | 111573519.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20250331 | Shares Issued | 112288759.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20240331 | Shares Withheld Related To Employee Tax Withholding Value | -42101000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 733546000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -6795000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-058129 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 846918000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Stock Issued During Period Shares Equity Incentive Awards | 715240.0000 | shares | 1 | 0000950170-25-058129 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20240331 | Stock Issued During Period Value New Issues | 637002000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20250331 | Treasury Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Additional Paid In Capital Common Stock | 1380669000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Available For Sale Securities Debt Securities Current | 0.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= Cash Equivalents; | ||
| 0000950170-25-058129 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 55516000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 26676000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Common Stock Shares Outstanding | 112288759.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Deposits Assets Noncurrent | 46000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Operating Lease Right Of Use Asset Amortization Expense | 74000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Operating Leases Interest Expense | 10000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20250331 | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | 9000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -1125000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20240331 | Other Nonoperating Income Expense | 6717000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Other Nonoperating Income Expense | 9840000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Prepaid Clinical Trial And Preclinical Study Costs | 3476000.0000 | USD | 0 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20240331 | Share Based Compensation | 2429000.0000 | USD | 1 | us-gaap/2024 | Award Type= Employee Stock Option; | ||
| 0000950170-25-058129 | 20240331 | Share Based Compensation | 496000.0000 | USD | 1 | us-gaap/2024 | Award Type= Employee Stock Purchase Plan; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 0.0000 | USD | 1 | us-gaap/2024 | Award Date= January Two Thousand Twenty Two; Award Type= Performance Based Restricted Stock Units; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 3200000.0000 | USD | 13 | us-gaap/2024 | Award Date= January Two Thousand Twenty Two; Award Type= Performance Based Restricted Stock Units; | ||
| 0000950170-25-058129 | 20240331 | Shares Withheld Related To Employee Tax Withholding Shares | -833711.0000 | shares | 1 | 0000950170-25-058129 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20241231 | Stockholders Equity | 880278000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -389000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 933891000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1368972000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20230731 | Stock Issued During Period Shares New Issues | 200000000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; Range= Maximum; Subsidiary Sale Of Stock= At The Market Equity Offering Sales Agreement; | ||
| 0000950170-25-058129 | 20240229 | Stock Issued During Period Shares New Issues | 7441650.0000 | shares | 0 | us-gaap/2024 | Subsidiary Sale Of Stock= March2024 Offering; | ||
| 0000950170-25-058129 | 20240331 | Stock Issued During Period Shares Share Based Compensation Gross | 2080857.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20241231 | Treasury Stock Common Shares | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 112069078.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 103457305.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Stock Issued During Period Value New Issues | 643797000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 112069078.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Additional Paid In Capital Common Stock | 1368972000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Amortization Of Financing Costs Equity Transactions | 24000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20241231 | Common Stock Shares Outstanding | 111573519.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Common Stock Value | 1000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Earnings Per Share Diluted | -0.2600 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Accounts Payable Current | 7702000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Accretion Amortization Of Discounts And Premiums Investments | 2821000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Accretion Amortization Of Discounts And Premiums Investments | 3133000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -788000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 195579000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 37940000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 140111000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 11263000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Change In Accrued Interest Relating To Marketable Securities Held As Investments | -2470000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20240331 | Increase Decrease In Accounts Payable | -2287000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Increase Decrease In Operating Lease Liability | -129000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Liabilities | 20075000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Liabilities And Stockholders Equity | 866993000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Net Cash Provided By Used In Operating Activities | -52331000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Other Accrued Liabilities Current | 11373000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Prepaid Expense And Other Assets Current | 1128000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees | 46658000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20240331 | Proceeds From Sale Maturity And Collections Of Investments | 136809000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Research And Development Expense | 41391000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 140000.0000 | USD | 1 | us-gaap/2024 | Award Type= Employee Stock Purchase Plan; | ||
| 0000950170-25-058129 | 20250331 | Stockholders Equity | 846918000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20231231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 348419000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20250331 | Treasury Stock Common Shares | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Unpaid Deferred Initial Public Offering And Other Financing Costs | 50000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20241231 | Common Stock Shares Authorized | 300000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Deposits Assets Noncurrent | 46000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Earnings Per Share Basic | -0.4100 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 9554000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Liabilities And Stockholders Equity | 908321000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Net Cash Provided By Used In Financing Activities | 606037000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Net Cash Provided By Used In Investing Activities | -459792000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Net Cash Provided By Used In Operating Activities | -6134000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Operating Expenses | 55469000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Operating Lease Right Of Use Asset | 1003000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -1125000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Payments To Acquire Investments | 232614000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Retained Earnings Accumulated Deficit | -487907000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Share Based Compensation | 5828000.0000 | USD | 1 | us-gaap/2024 | Income Statement Location= General And Administrative Expense; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 11500000.0000 | USD | 1 | us-gaap/2024 | Award Date= January Two Thousand Twenty Four; Award Type= Performance Based Restricted Stock Units; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 130000.0000 | USD | 1 | us-gaap/2024 | Award Date= January Two Thousand Twenty Three; Award Type= Performance Based Restricted Stock Units; | ||
| 0000950170-25-058129 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1340789000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20240331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -405300000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-058129 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20240331 | Unpaid Deferred Initial Public Offering And Other Financing Costs | 69000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 103457305.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Accounts Payable Current | 9813000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Assets Current | 866023000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Available For Sale Securities Debt Securities Current | 875936000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Common Stock Shares Issued | 111573519.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Common Stock Shares Issued | 112288759.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Comprehensive Income Net Of Tax | -45057000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Earnings Per Share Basic | -0.2600 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | General And Administrative Expense | 9970000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Interest Income Expense Nonoperating Net | 6745000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Liabilities | 28043000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Liabilities Current | 19573000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Operating Lease Liability Current | 498000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Payments Related To Tax Withholding For Share Based Compensation | 42101000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Preferred Stock Value | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-058129 | 20240331 | Profit Loss | -27356000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 4000000.0000 | USD | 1 | us-gaap/2024 | Award Date= January Two Thousand Twenty Five; Award Type= Performance Based Restricted Stock Units; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 4248000.0000 | USD | 1 | us-gaap/2024 | Award Type= Employee Stock Option; | ||
| 0000950170-25-058129 | 20240331 | Shares Withheld Related To Employee Tax Withholding Value | -42101000.0000 | USD | 1 | 0000950170-25-058129 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 1380669000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20240331 | Stock Issued During Period Value New Issues | 6795000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-058129 | 20250331 | Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition | 11348000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition | 11348000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20241231 | Assets Current | 907216000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Common Stock Value | 1000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Deferred Financing Costs Non Current | 56000.0000 | USD | 0 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20240331 | Net Income Loss | -27356000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Net Income Loss | -45629000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-058129 | 20250331 | Operating Lease Liability Noncurrent | 502000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | -85000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 563000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20240331 | Payments Of Proceeds From Public Offering Net Of Offering Costs | -597119000.0000 | USD | 1 | 0000950170-25-058129 | |||
| 0000950170-25-058129 | 20250331 | Profit Loss | -45629000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Share Based Compensation | 766000.0000 | USD | 0 | us-gaap/2024 | Award Date= January Two Thousand Twenty One; Award Type= Performance Based Restricted Stock Units; | ||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 11348000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20250331 | Share Based Compensation | 6960000.0000 | USD | 1 | us-gaap/2024 | Award Type= Restricted Stock And Restricted Stock Units; | ||
| 0000950170-25-058129 | 20240331 | Shares Issued | 110228869.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 880278000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -788000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-058129 | 20241231 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -487907000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-058129 | 20250331 | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -533536000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-058129 | 20240331 | Stock Issued During Period Shares New Issues | 8867953.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-058129 | 20250331 | Stock Issued During Period Shares New Issues | 1426303.0000 | shares | 7 | us-gaap/2024 | Equity Components= Common Stock; Subsidiary Sale Of Stock= At The Market Equity Offering Sales Agreement; | ||
| 0000950170-25-058129 | 20240331 | Stock Issued During Period Value Share Based Compensation Gross | 4361000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-058129 | 20240331 | Stock Issued During Period Value Share Based Compensation Gross | 4361000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-058129 | 20241231 | Treasury Stock Value | 0.0000 | USD | 0 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees | 0000950170-25-058129 | 1 | 0 | monetary | D | D | Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees | Proceeds from issuance of at-the-market equity offering sales agreement net of fees. |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Including Portion Attributable to Noncontrolling Interest | Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Available For Sale Securities Debt Securities Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Debt Securities, Available-for-Sale, Current | Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. |
| Interest Income Expense Nonoperating Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Income (Expense), Nonoperating | Amount of interest income (expense) classified as nonoperating. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Stock Issued During Period Value Share Based Compensation Gross | us-gaap/2024 | 0 | 0 | monetary | D | C | Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture | Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). |
| Shares Withheld Related To Employee Tax Withholding Value | 0000950170-25-058129 | 1 | 0 | monetary | D | D | Shares Withheld Related To Employee Tax Withholding Value | Values of shares withheld related to employee tax withholding. |
| Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Shares, Issued | Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. | |
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax | Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Payments To Acquire Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Investments | The cash outflow associated with the purchase of all investments (debt, security, other) during the period. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Treasury Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Treasury Stock, Value | The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition | Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised | Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Stock Issued During Period Shares Share Based Compensation Gross | us-gaap/2024 | 0 | 0 | shares | D | Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture | Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). | |
| Amortization Of Financing Costs Equity Transactions | 0000950170-25-058129 | 1 | 0 | monetary | D | D | Amortization Of Financing Costs Equity Transactions | Amortization of financing costs equity transactions. |
| Stock Issued During Period Values Equity Incentive Awards | 0000950170-25-058129 | 1 | 0 | monetary | D | C | Stock Issued During Period Values Equity Incentive Awards | Stock issued during period, values, equity incentive awards. |
| Unpaid Deferred Initial Public Offering And Other Financing Costs | 0000950170-25-058129 | 1 | 0 | monetary | D | C | Unpaid Deferred Initial Public Offering And Other Financing Costs | Unpaid deferred initial public offering and financing costs. |
| Stock Issued During Period Shares Equity Incentive Awards | 0000950170-25-058129 | 1 | 0 | shares | D | Stock Issued During Period, Shares, Equity Incentive Awards | Stock issued during period, shares, equity incentive awards. | |
| Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Noncurrent | Amount of obligation due after one year or beyond the normal operating cycle, if longer. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Deferred Financing Costs Non Current | 0000950170-25-058129 | 1 | 0 | monetary | I | D | Deferred Financing Costs Non Current | Deferred financing costs noncurrent. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Change In Accrued Interest Relating To Marketable Securities Held As Investments | 0000950170-25-058129 | 1 | 0 | monetary | D | C | Change In Accrued Interest Relating To Marketable Securities Held As Investments | Change in accrued interest relating to marketable securities held as investments. |
| Prepaid Clinical Trial And Preclinical Study Costs | 0000950170-25-058129 | 1 | 0 | monetary | I | D | Prepaid Clinical Trial And Preclinical Study Costs | Prepaid clinical trial and preclinical study costs. |
| Shares Withheld Related To Employee Tax Withholding Shares | 0000950170-25-058129 | 1 | 0 | shares | D | Shares Withheld Related To Employee Tax Withholding Shares | Number of shares withheld related to employee tax withholding, | |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Lease, Right-of-Use Asset, Periodic Reduction | Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. |
| Other Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Accrued Liabilities, Current | Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. |
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment, Tax Withholding, Share-Based Payment Arrangement | Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Payments Of Proceeds From Public Offering Net Of Offering Costs | 0000950170-25-058129 | 1 | 0 | monetary | D | C | Payments Of Proceeds From Public Offering Net Of Offering Costs | Payments of proceeds from public offering net of offering costs. |
| Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Accretion (Amortization) of Discounts and Premiums, Investments | The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Operating Leases Interest Expense | 0000950170-25-058129 | 1 | 0 | monetary | D | D | Operating Leases Interest Expense | Operating leases interest expense. |
| Treasury Stock Common Shares | us-gaap/2024 | 0 | 0 | shares | I | Treasury Stock, Common, Shares | Number of previously issued common shares repurchased by the issuing entity and held in treasury. | |
| Deposits Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Deposits Assets, Noncurrent | Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Proceeds From Sale Maturity And Collections Of Investments | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale, Maturity and Collection of Investments | The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-058129 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-058129 | 6 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-058129 | 2 | 4 | BS | 0 | H | Available For Sale Securities Debt Securities Current | us-gaap/2024 | Short-term investments available for sale | 0 |
| 0000950170-25-058129 | 2 | 5 | BS | 0 | H | Prepaid Clinical Trial And Preclinical Study Costs | 0000950170-25-058129 | Prepaid clinical trial and preclinical study costs | 0 |
| 0000950170-25-058129 | 2 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0000950170-25-058129 | 2 | 7 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-058129 | 2 | 8 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Right-of-use assets | 0 |
| 0000950170-25-058129 | 2 | 9 | BS | 0 | H | Deferred Financing Costs Non Current | 0000950170-25-058129 | Deferred financing costs | 0 |
| 0000950170-25-058129 | 2 | 10 | BS | 0 | H | Deposits Assets Noncurrent | us-gaap/2024 | Deposits | 0 |
| 0000950170-25-058129 | 2 | 11 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-058129 | 2 | 14 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-058129 | 2 | 15 | BS | 0 | H | Other Accrued Liabilities Current | us-gaap/2024 | Other accrued liabilities | 0 |
| 0000950170-25-058129 | 2 | 16 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Lease liability, current | 0 |
| 0000950170-25-058129 | 2 | 17 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-058129 | 2 | 18 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Lease liability, net of current portion | 0 |
| 0000950170-25-058129 | 2 | 19 | BS | 0 | H | Liabilities Noncurrent | us-gaap/2024 | Total long-term liabilities | 0 |
| 0000950170-25-058129 | 2 | 20 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000950170-25-058129 | 2 | 21 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 7) | 0 |
| 0000950170-25-058129 | 2 | 23 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024 | 0 |
| 0000950170-25-058129 | 2 | 24 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; 112,288,759 shares issued and outstanding at March 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024 | 0 |
| 0000950170-25-058129 | 2 | 25 | BS | 0 | H | Treasury Stock Value | us-gaap/2024 | Treasury stock at cost, no shares at March 31, 2025 and December 31, 2024 | 1 |
| 0000950170-25-058129 | 2 | 26 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000950170-25-058129 | 2 | 27 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-058129 | 2 | 28 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0000950170-25-058129 | 2 | 29 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders equity | 0 |
| 0000950170-25-058129 | 2 | 30 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders equity | 0 |
| 0000950170-25-058129 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value | 0 |
| 0000950170-25-058129 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized | 0 |
| 0000950170-25-058129 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued | 0 |
| 0000950170-25-058129 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding | 0 |
| 0000950170-25-058129 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0000950170-25-058129 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0000950170-25-058129 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0000950170-25-058129 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0000950170-25-058129 | 3 | 9 | BS | 1 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury stock, shares | 0 |
| 0000950170-25-058129 | 4 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Revenues | 0 |
| 0000950170-25-058129 | 4 | 3 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-058129 | 4 | 4 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0000950170-25-058129 | 4 | 5 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0000950170-25-058129 | 4 | 6 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0000950170-25-058129 | 4 | 8 | IS | 0 | H | Amortization Of Financing Costs Equity Transactions | 0000950170-25-058129 | Amortization of financing costs | 1 |
| 0000950170-25-058129 | 4 | 9 | IS | 0 | H | Interest Income Expense Nonoperating Net | us-gaap/2024 | Interest income, net | 0 |
| 0000950170-25-058129 | 4 | 10 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Total other income, net | 0 |
| 0000950170-25-058129 | 4 | 11 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-058129 | 4 | 13 | IS | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2024 | Unrealized gain (loss) on securities | 0 |
| 0000950170-25-058129 | 4 | 14 | IS | 0 | H | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | us-gaap/2024 | Foreign currency translation loss | 0 |
| 0000950170-25-058129 | 4 | 15 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive loss | 0 |
| 0000950170-25-058129 | 4 | 16 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic net loss per common share | 0 |
| 0000950170-25-058129 | 4 | 17 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted net loss per common share | 0 |
| 0000950170-25-058129 | 4 | 18 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Weighted-average shares used to compute basic net loss per share | 0 |
| 0000950170-25-058129 | 4 | 19 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Weighted-average shares used to compute diluted net loss per share | 0 |
| 0000950170-25-058129 | 5 | 10 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Balance | 0 |
| 0000950170-25-058129 | 5 | 11 | EQ | 0 | H | Shares Issued | us-gaap/2024 | Balance (in shares) | 0 |
| 0000950170-25-058129 | 5 | 12 | EQ | 0 | H | Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition | us-gaap/2024 | Employee stock-based compensation, net | 0 |
| 0000950170-25-058129 | 5 | 13 | EQ | 0 | H | Shares Withheld Related To Employee Tax Withholding Value | 0000950170-25-058129 | Shares withheld related to employee tax withholding | 0 |
| 0000950170-25-058129 | 5 | 14 | EQ | 0 | H | Shares Withheld Related To Employee Tax Withholding Shares | 0000950170-25-058129 | Shares withheld related to employee tax withholding (in shares) | 0 |
| 0000950170-25-058129 | 5 | 15 | EQ | 0 | H | Stock Issued During Period Value Share Based Compensation Gross | us-gaap/2024 | Issuance of common stock under employee stock plans | 0 |
| 0000950170-25-058129 | 5 | 16 | EQ | 0 | H | Stock Issued During Period Shares Share Based Compensation Gross | us-gaap/2024 | Issuance of common stock under employee stock plans (in shares) | 0 |
| 0000950170-25-058129 | 5 | 17 | EQ | 0 | H | Stock Issued During Period Values Equity Incentive Awards | 0000950170-25-058129 | Issuance of common stock for equity incentive awards | 0 |
| 0000950170-25-058129 | 5 | 18 | EQ | 0 | H | Stock Issued During Period Shares Equity Incentive Awards | 0000950170-25-058129 | Issuance of common stock for equity incentive awards, shares | 0 |
| 0000950170-25-058129 | 5 | 19 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Sale of common stock, net of issuance costs | 0 |
| 0000950170-25-058129 | 5 | 20 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Sale of common stock, net of issuance costs (in shares) | 0 |
| 0000950170-25-058129 | 5 | 21 | EQ | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2024 | Unrealized gain (loss) on investments | 0 |
| 0000950170-25-058129 | 5 | 22 | EQ | 0 | H | Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | us-gaap/2024 | Unrealized currency translation loss | 0 |
| 0000950170-25-058129 | 5 | 23 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-058129 | 5 | 24 | EQ | 0 | H | Stockholders Equity Including Portion Attributable To Noncontrolling Interest | us-gaap/2024 | Balance | 0 |
| 0000950170-25-058129 | 5 | 25 | EQ | 0 | H | Shares Issued | us-gaap/2024 | Balance (in shares) | 0 |
| 0000950170-25-058129 | 6 | 4 | CF | 0 | H | Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | Amortization of investment premiums | 1 |
| 0000950170-25-058129 | 6 | 5 | CF | 0 | H | Amortization Of Financing Costs Equity Transactions | 0000950170-25-058129 | Amortization of financing costs | 0 |
| 0000950170-25-058129 | 6 | 6 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0000950170-25-058129 | 6 | 7 | CF | 0 | H | Operating Lease Right Of Use Asset Amortization Expense | us-gaap/2024 | Amortization of right-of-use assets | 0 |
| 0000950170-25-058129 | 6 | 8 | CF | 0 | H | Operating Leases Interest Expense | 0000950170-25-058129 | Interest expense related to operating lease liability | 0 |
| 0000950170-25-058129 | 6 | 10 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0000950170-25-058129 | 6 | 11 | CF | 0 | H | Change In Accrued Interest Relating To Marketable Securities Held As Investments | 0000950170-25-058129 | Accrued interest, net of interest receivable on maturity of investments | 1 |
| 0000950170-25-058129 | 6 | 12 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-058129 | 6 | 13 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses | 0 |
| 0000950170-25-058129 | 6 | 14 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Lease liability | 0 |
| 0000950170-25-058129 | 6 | 15 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0000950170-25-058129 | 6 | 17 | CF | 0 | H | Payments To Acquire Investments | us-gaap/2024 | Purchases of investments | 1 |
| 0000950170-25-058129 | 6 | 18 | CF | 0 | H | Proceeds From Sale Maturity And Collections Of Investments | us-gaap/2024 | Proceeds from maturities of investments | 0 |
| 0000950170-25-058129 | 6 | 19 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash provided by (used in) investing activities | 0 |
| 0000950170-25-058129 | 6 | 21 | CF | 0 | H | Payments Of Proceeds From Public Offering Net Of Offering Costs | 0000950170-25-058129 | Public offering, net of offering costs | 1 |
| 0000950170-25-058129 | 6 | 22 | CF | 0 | H | Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | Value of shares withheld related to employee tax withholding | 1 |
| 0000950170-25-058129 | 6 | 23 | CF | 0 | H | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | us-gaap/2024 | Proceeds from exercises of stock options and other stock issuances | 0 |
| 0000950170-25-058129 | 6 | 24 | CF | 0 | H | Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees | 0000950170-25-058129 | ATM offering, net of fees | 0 |
| 0000950170-25-058129 | 6 | 25 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0000950170-25-058129 | 6 | 26 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | us-gaap/2024 | Net increase (decrease) in cash and cash equivalents | 0 |
| 0000950170-25-058129 | 6 | 27 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents beginning of period | 0 |
| 0000950170-25-058129 | 6 | 28 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Effect of exchange rate changes on cash | 0 |
| 0000950170-25-058129 | 6 | 29 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash and cash equivalents end of period | 0 |
| 0000950170-25-058129 | 6 | 31 | CF | 0 | H | Unpaid Deferred Initial Public Offering And Other Financing Costs | 0000950170-25-058129 | Unpaid deferred public offering and other financing costs | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |